Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif., January 05, 2026--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist") announced the submission of a New Drug ...

Takeda & Protagonist submit NDA to US FDA seeking approval for rusfertide to treat polycythemia vera: Osaka, Japan Wednesday, January 7, 2026, 17:00 Hrs [IST] Takeda, focused on c ...

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 ...

New York, USA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment BESREMi is a preferred, FDA-approved option for both ...

Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight Polycythemia Pipeline constitutes 10+ key ...

NEWARK, Calif., June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG ...

Yesterday the FDA approved Jakafi (Ruxolitinib), a pill, for use in treating polycythemia vera (p. vera). The drug, a targeted kinase inhibitor manufactured by Incyte, offers a needed option for some ...

Global Polycythemia Vera Treatment Market Report added by DBMR research scrutinizes the overall market synopsis globally, their restraining factors, market drivers, major challenges, opportunities, ...